Motion Sickness Relief Tablet
NDC Package 50844-199-02
Package Information
Motion Sickness Relief (dimenhydrinate) tablets is dimenhydrinate is an antihistamine used to prevent and treat nausea, vomiting and dizziness caused by motion sickness when medication cannot be given by mouth. This formulation utilizes a tablet delivery system. Marketed by L.n.k. International, Inc., this product is identified by NDC 50844-199 and is authorized under FDA application M009.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50844 - L.n.k. International, Inc.
- 50844-199 - Motion Sickness Relief
- 50844-199-02 - 2 BLISTER PACK in 1 CARTON / 6 TABLET in 1 BLISTER PACK
- 50844-199 - Motion Sickness Relief
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50844-199-02 identifies a specific commercial package of 2 blister pack in 1 carton / 6 tablet in 1 blister pack of Motion Sickness Relief, a human over the counter drug labeled by L.n.k. International, Inc.. This tablet is formulated for oral use and contains dimenhydrinate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by L.n.k. International, Inc. on December 01, 1992. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Dimenhydrinate is an antihistamine used to prevent and treat nausea, vomiting and dizziness caused by motion sickness when medication cannot be given by mouth. Dimenhydrinate injection should not be used in newborns because of an increased risk of side effects.
How is this L.n.k. International, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50844019902. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.